An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Capmatinib (Primary)
- Indications Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 20 Feb 2018 Status changed from recruiting to completed.
- 05 Apr 2017 Planned End Date changed from 1 Sep 2017 to 30 Aug 2017.
- 05 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Aug 2017.